Genetic instability in animal tumorigenesis models

Cancer Surveys

Volumn 29, Issue , 1997, Pages 329-352

  Donehower, Larry A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; CARCINOGENESIS; CELL CYCLE; DNA REPAIR; GENETIC STABILITY; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATOR GENE; REVIEW; TELOMERE;

ANIMALS; CELL CYCLE; CYCLINS; DISEASE MODELS, ANIMAL; DNA DAMAGE; DNA REPAIR; GENES, P53; GENES, RETINOBLASTOMA; MICE; MUTAGENESIS; NEOPLASMS; TELOMERASE; TELOMERE;

EID: 0030909553     PISSN: 02612429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (153)

1. Agarwal ML, Agarwal A, Taylor WR and Stark GR (1995) p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proceedings of the National Academy of Sciences of the USA 92 8493-8497
2. Almasan A, Linke SP, Paulson TG, Huang L-C and Wahl G (1995a) Genetic instability as a consequence of inappropriate entry into and progression through S phase. Cancer and Metastasis Reviews 14 59-73
3. Almasan A, Yin Y, Kelly RE et al (1995b) Deficiency of retinoblastoma protein leads to in-appropriate S-phase entry, activation of E2F-responsive genes and apoptosis. Proceedings of the National Academy of Sciences of the United States of America 92 5436-5440
4. Asano K, Sakamoto H, Sasaki H et al (1995) Tumorigenicity and gene amplification potentials of cyclin D1-overexpressing NIH3T3 cells. Biochemical and Biophysical Research Communications 217 1169-1176
5. Bagchi S, Weinmann R and Raychaudhuri P (1991) The retinoblastoma protein copurifies with E2F-1, an E1A-regulated inhibitor of the transcription factor E2F. Cell 65 1063-1072
6. Bakalkin G, Yakovleva T, Selivanova G et al (1994) p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proceedings of the National Academy of Sciences of the USA 91 413-417
7. Baker SM, Bronner CE, Zhang L et al (1995) Male mice defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis. Cell 82 309-319
8. Bates S and Vousden KH (1996) p53 in signaling checkpoint arrest or apoptosis. Current Opinion in Genetics and Development 6 12-19
9. Bischoff FZ, Yim SO, Pathak S et al (1990) Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization. Cancer Research 50 7979-7984
10. Blasco MA, Rizen M, Greider CW and Hanahan D (1996) Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. Nature Genetics 12 200-204
11. Broccoli D, Godley LA, Donehower LA, Varmus HE and de Lange T (1996) Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation. Molecular and Cellular Biology 16 3765-3772
12. Brugarolas, J, Chandrasekaran, C, Gordon JI et al (1995) Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377 552-557
13. Capecchi MR (1989) Altering the genome by homologous recombination. Science 244 1288-1292
14. Cavenee WK, Hansen MF, Nordenskjold M et al (1985) Genetic origin of mutations predisposing to retinoblastoma. Science 228 501-503
15. Chadeneau C, Siegel P, Harley CB, Muller WJ and Bacchetti S (1995) Telomerase activity in normal and malignant murine tissues. Oncogene 11 893-898
16. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM and Nevins JR (1991) The E2F transcription factor is a cellular target for the RB protein. Cell 65 1053-1062
17. Christofori G and Hanahan D (1994) Molecular dissection of multi-stage tumorigenesis in transgenic mice. Seminars in Cancer Biology 5 3-12
18. Clarke AR, Maandag ER, van Roon M et al (1992) Requirement for a functional Rb-1 gene in murine development. Nature 359 328-330
19. Coates PJ, Save V, Ansari B and Hall PA (1995) Demonstration of DNA damage/repair in individual cells using in situ end labelling: association of p53 with sites of DNA damage. Journal of Pathology 176 19-26
20. Cross SM, Sanchez CA, Morgan CA et al (1995) A p53-dependent mouse spindle checkpoint. Science 267 1353-1356
21. de Lange T (1995) Telomere dynamics and genome instability in human cancer, In: Blackburn EH and Greider CW (eds). Telomeres, pp. 265-293, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
22. Deng C, Zhang P, Harper JW, Elledge SJ and Leder P (1995) Mice lacking p21CIP1/WAF1CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82 675-684
23. De Vries A, Van Oostrom CTM, Hofhuis FMA et al (1995) Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature 377 169-173
24. de Wind N, Dekker, Berns A, Radman M and te Riele H (1995) Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation toleration tolerance, hyper-recombination and predisposition to cancer. Cell 82 321-330
25. Donehower LA, Harvey M, Slagle BL et al (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356 215-221
26. Donehower LA, Godley LA, Aldaz CM et al (1995) Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes and Development 9 882-895
27. Donehower LA, Harvey M, Vogel H et al (1995) Effects of genetic background on tumorigenesis in p53-deficient mice. Molecular Carcinogenesis 14 16-22
28. dos Santos CC, Gavish H and Buchwald M (1994) Fanconi anemia revisited: old ideas and new advances. Stem Cells 12 142-153
29. Dulic, V, Kaufmann WK, Wilson SJ et al (1994) p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76 1013-1023
30. Dutta A, Ruppert JM, Aster JC and Winchester E (1993) Inhibition of DNA replication factor RPA by p53. Nature 365 79-82
31. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW and Vogelstein B (1992) Definition of a consensus binding site for p53. Nature Genetics 1 45-49
32. El-Deiry WS, Tokino T, Velculescu VE et al (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 76 817-825
33. El-Deiry WS, Harper JW, O'Connor PM et al (1994) WAF1/GIP1 is induced in p53 mediated G1 arrest and apoptosis. Cancer Research 4 1169-1174
34. Elledge SJ, Winston J and Harper JW (1996) A question of balance: the role of cyclin-kinase inhibitors in development and tumorigenesis.Trends in Cell Biology 6 388-392
35. Eshleman JR and Markowitz SD (1995) Microsatellite instability in inherited and sporadic neoplasms. Current Opinion in Oncology 7 83-89
36. Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R and Prives C (1992) Wild-type p53 activates transcription in vitro. Nature 358 83-86
37. Fearon ER and Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61 759-767
38. Fishel R, Lescoe MK, Rao MRS et al (1993) The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75 1027-1038
39. Flores-Rozas H, Kelman Z, Dean F et al (1994) Cdk-interacting protein 1 directly binds with PCNA and inhibits replication catalyzed by the DNA polymerase d holoenzyme. Proceedings of the National Academy of Sciences of the USA 91 8655-8659
40. Ford JM and Hanawalt PC (1995) Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in globals DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Proceedings of the National Academy of Sciences of the USA 92 8876-8880
41. Frohman MA and Martin GR (1989) Cut, paste and save: new approaches to altering specific genes in mice. Cell 56 145-147
42. Fukasawa K, Choi T, Kuriyama R, Rulong S and Van de Woude GF (1996) Abnormal centrosome amplification in the absence of p53. Science 271 1744- 1747
43. Greenblatt MS, Bennett W, Hollstein M and Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Research 54 4855-4878
44. Gu Y, Turck CW and Morgan DO (1993) Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366 707-710
45. Halevy O, Novitch BG, Spicer DB et al (1995) Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21CIP1/WAF1 by MyoD. Science 267 1018-1021
46. Hamel PA, Phillips RA, Muncaster M and Gallie BL (1993) Speculations on the roles of RB1 in tissue-specific differentiation, tumor initiation and tumor progression. FASEB Journal 7 846-854
47. Hanahan D (1989) Transgenic mice as probes into complex systems. Science 246 1265-1275
48. Hanawalt P (1994) Transcription-coupled repair and human disease. Science 266 1957-1960
49. Harley CB, Kim NW, Prowse KR et al (1994) Telomerase, cell immortality and cancer. Cold Spring Harbor Symposia on Quantitative Biology 59 307-315
50. Harlow E (1992) For our eyes only. Nature 359 270-271
51. Harper JW and Elledge SJ (1996) Cdk inhibitors in development and cancer Current Opinions in Genetics and Development 6 56-64
52. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ (1993) The p21CIP1/WAF1 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75 805-816
53. Harper JW, Elledge SJ, Keyomarsi K et al (1995) Inhibition of cyclin-dependent kinases by p21CIP1/WAF1. Molecular Biology of the Cell 6 387-400
54. Hartwell L (1992) Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71 543-546
55. Hartwell L and Kastan M (1994) Cell cycle control and cancer. Science 266 1821-1828
56. Hartwell L, Weinert T, Kadyk L and Garvik B (1994) Cell cycle checkpoints, genomic integrity and cancer. Cold Spring Harbor Symposia on Quantitative Biology 59 259-263
57. Harvey M, Sands AT, Weiss RS et al (1993) In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 8 2457-2467
58. Hatekeyama M, Herrera RA, Makela T, Dowdy SF, Jacks T and Weinberg RA (1994) The cancer cell and the cell cycle clock. Cold Spring Harbor Symposia on Quantitative Biology 59 1-10
59. Havre PA, Yuan J, Hedrick L, Chu KR and Glazer PM (1993) p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Research 55 4420-4424
60. Herrera RE, Sah VP, Williams BO, Makela TP, Weinberg RA and Jacks T (1996) Altered cell cycle kinetics, gene expression and G1 restriction point regulation in Rb-deficient fibroblasts. Molecular and Cellular Biology 16 2402-2407
61. Hirama T and Koeffler HP (1995) Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86 841-854
62. Howes KA, Ransom LN, Papermaster DS, Lasudry JGH, Albert DM, and Windle JJ (1994) Apoptosis or retinoblastoma - alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes and Development 8 1300-1310
63. Hu N, Gutsmann A, Herbert DC, Bradley A, Lee WH and Lee EYHP (1994) Heterozygous Rb-1 delta/+ mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 9 1021-1027
64. Hunter T and Pines J (1994) Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79 573-582
65. Imai Y, Matsushima Y, Sugimura T and Terada M (1991) Purification and characterization of human papillomavirus type 16 E7 protein with preferential binding capacity to the un-derphosphorylated form of retinoblastoma gene product. Journal of Virology 65 4966
66. Ishizaki K, Ejima T, Matsunaga R et al (1994) Increased UV-induced SCEs but normal repair of DNA damage in p53-deficient mouse cells. International Journal of Cancer 57 254-257
67. Jacks TA, Fazeli E, Schmitt E, Bronson RT, Goodell M and Weinberg RA (1992) Effects of an RB·mutation in the mouse. Nature 359 295-300
68. Jacks T, Remington L, Williams BO et al (1994) Tumor spectrum analysis in p53-mutant mice. Current Biology 4 1-7
69. Jares P, Fernandez PL, Campo E et al (1994) The PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Research 54 4813-4817
70. Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH and Weinstein IB (1992) Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Research 52 2980-2983
71. Jiang W, Kahn SM, Zhou P, Zhang Y-J et al (1993) Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene 8 3447-3457
72. Jones SN, Donehower LA and Bradley A (1995) Analysis of tumor suppressor genes using transgenic mice. Methods: A Companion to Methods in Enzymology 8 247-258
73. Kamb A, Gruis NA, Weaver-Feldbaus J et al (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264 436-440
74. Kastan MB, Canman CE and Leonard CJ (1995) p53, cell cycle control and apoptosis: implications for cancer. Cancer and Metastasis Reviews 14 3-15
75. Kim NW, Piatyszek, Prowse KR et al (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266 2011-2015
76. Kipling D and Cooke HJ (1990) Hypervariable ultra-long telomeres in mice. Nature 347 347-402
77. Kirsch IR, Abdallah JM, Bertness VL et al (1994) Lymphocyte-specific genetic instability and cancer. Cold Spring Harbor Symposia on Quantitative Biology 59 287-295
78. Kiyokawa H, Kineman RD, Mahova-Todorova KO et al (1996) Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1 . Cell 85 721-732
79. Knudson AG (1971) Mutation and cancer: statistical study of retinoblastoma. Proceedings of the National Academy of Sciences of the USA 68 820-823
80. Knudson AG (1993) Antioncogenes and human cancer. Proceedings of the National Academy of Sciences of the USA 90 10914-10921
81. Ko LJ and Prives C (1996) p53: puzzle and paradigm. Genes and Development 10 1054-1072
82. Kolodner RD (1995) Mismatch repair: mechanisms and relationship to cancer susceptibility. Trends in Biochemical Sciences 20 397-401
83. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB (1992) Wild-type p53 is a cell cycle check-point determinant following irradiation. Proceedings of the National Academy of Sciences of the USA 89 7491-7495
84. Lammie GA, Fantl V, Smith R et al (1991) D11S128, a putative oncogene on chromosome 11q13 is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 6 439-444
85. Lane DP (1992) p53, guardian of the genome. Nature 358 15-16
86. Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T and Bernstein A (1989) High incidence of lung, bone and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Molecular and Cellular Biology 9 3882-3991
87. Lazar V, Grandjouan S, Bognel C et al (1994) Accumulation of multiple mutations in tumour suppressor genes during colorectal tumorigenesis in HNPCC patients. Human Molecular Genetics 3 2257-2260
88. Leach FS, Nicolaides NC, Papadopoulos N et al (1993) Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75 1215-1225
89. Lee EYHP, Chang CY, Hu NP et al (1992) Mice deficient for RB are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359 288-294
90. Lee EYHP, Hu NP, Yuan SSF et al (1994) Dual roles of the retinoblastoma in cell cycle regulation and neuron differentiation. Genes and Development 8 2008-2021
91. Lee S, Elenbaas B, Levine A and Griffith J (1995) p53 and its 14 kD C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81 1013-1020
92. Lehmann AR (1995) Nucleotide excision repair and the link with transcription. Trends in Biochemical Sciences 20 402-405
93. Leveillard T, Andera L, Bissonnette N et al (1996) Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO Journal 15 1615-1624
94. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T and Tlsty TD (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild type p53. Cell 70 605-620
95. Loeb LA (1991) Mutator phenotype may be required for multistage carcinogenesis Cancer Research 51 3075-3079
96. Lu X and Lane DP (1993) Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 75 765-778
97. Ludlow JW, DeCaprio JA, Huang CM, Lee WH, Paucha E and Livingston D (1989) SV40 large T antigen binds preferentially to an underphosphorylated member of the retinoblastoma susceptibility gene product family. Cell 56 57-65
98. Lukas J, Parry D, Aagaard L et al (1995) Retinoblastoma-protein-dependent cell cycle inhibition by the tumour suppressor p 16. Nature 375 503-506
99. Macleod KF, Sherry N, Hannon G et al (1995) p53-dependent and independent expression of p21CIP1/WAF1 during cell growth, differentiation and DNA damage. Genes and Development 9 935-944
100. Malkin D, Li FP, Strong LC et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 250 1233-1238
101. Medema RH, Herrera RE, Lam F and Weinberg RA (1995) Growth suppression by p16ink4 requires functional retinoblastoma protein. Proceedings of the National Academy of Sciences of the USA 92 6289-6293
102. Meyn MS, Strasfeld L and Allen C (1994) Testing the role of p53 in the expression of genetic instability and apoptosis in ataxia telangiectasia. International Journal of Radiation Biology 66 (Supplement 6) S141-S149
103. Morgenbesser SD, Williams BO, Jacks T and DePinho RA (1994) p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 371 72-74
104. Motokura T, Bloom T, Kim HG et al (1991) A novel cyclin encoded by a bcl-linked candidate oncogene. Nature 350 512-515
105. Nakane H, Takeuchi S, Yuba S et al (1995) High incidence of ultraviolet-B- or chemical-carcinogen-induced skin tumours in mice lacking the xeroderma pigmentosum group A gene. Nature 377 165 168
106. Nakayama K, Ishida N, Shirane M et al (1996) Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85 707-720
107. Nicolaides NC, Papadopoulos N, Liu B et al (1994) Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 371 75-80
108. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368 753-756
109. Noda A, Ning Y, Venable SF, Pereira-Smith OM and Smith JR (1994) Cloning of cell-derived inhibitory of DNA synthesis using an expression screen. Experimental Cell Research 211 90-98
110. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194 23-28
111. Oberosler P, Hloch P, Ramsperger U and Stahl H (1993) p53-catalyzed annealing of complementary single-stranded nucleic acids. EMBO Journal 12 2389-2396
112. Okamoto A, Demetrick DJ, Spillare EA et al (1994) Mutations and altered expression of p16INK4 in human cancer. Proceedings of the National Academy of Sciences of the USA 91 11045-11049
113. Pan HC and Griep AE (1994) Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice-implications for tumor suppressor gene function in development. Genes and Development 8 1285-1299
114. Papadopoulos N, Nicolaides NC, Wei Y-F et al (1994) Mutation of a mutL homolog in hereditary colon cancer. Science 263 1625-1629
115. Parker SB, Eichele G, Zhang P et al (1995) p53-independent expression of p21CIP1/WAF1Cip1 in muscle and other terminally defferentiating cells. Science 267 1024-1027
116. Pollock PM, Pearson JV and Hayward NK (1996) Compilation of somatic mutations of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes, Chromosomes and Cancer 15 77-88
117. Polyak K, Kato JY, Solomon MJ et al (1994) p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes and Development 8 9-22
118. Prowse KR and Greider CW (1995) Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proceedings of the National Academy of Sciences of the USA 92 4818-4822
119. Purdie CA, Harrison DJ, Peter A et al (1994) Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 9 603-609
120. Quelle DE, Ashmun RA, Shurtleff SA et al (1993) Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes and Development 7 1559-1571
121. Raycroft L, Wu H and Lozano G (1990) Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249 1049-1051
122. Reed MB, Woelker P, Wang Y, Wang ME anderson ME and Tegtmeyer P (1995) The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proceedings of the National Academy of Sciences of the USA 92 9455-9459
123. Resnitzky D, Gossen M, Bujard H and Reed SI (1994) Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Molecular and Cellular Biology 14 1669-1679
124. Reznikoff CA, Belair C, Savelieva E et al (1994) Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6- immortalized human uroepiethelial cells. Genes and Development 8 2227-2240
125. Sancar A (1995) Excision repair in mammalian cells. Journal of Biological Chemistry 270 15915-15918
126. Sands AT, Abuin A, Sanchez A, Conti C and Bradley A (1995a) High susceptibility to ultraviolet-induced carcinogenesis in mice lacking XPC. Nature 377 162-165
127. Sands AT, Suraokar MB, Sanchez A, Marth JE, Donehower LA and Bradley A (1995b) p53 deficiency does not affect the accumulation of point mutations in a transgene target. Proceedings of the National Academy of Sciences of the USA 92 8517-8521
128. Serrano M, Hannon GJ and Beach D (1993) A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366 704-707
129. Serrano M, Lee H-W, Chin L, Cordon-Cardo C, Beach D and DePinho RA (1996) Role of the INK4a Locus in tumor suppression and cell mortality. Cell 85 27-37
130. Shapiro GI and Rollins BJ (1996) p16(INK4A) as a human tumor suppressor. Biochimica et Biophysica Acta Reviews on Cancer 1242 165-170
131. Sherr CJ, Kato J, Quelle DE, Matsuoka M and Roussel MF (1994) D-type cyclins and their cyclin-dependent kinases: G1 phase integrators of the mitogenic response. Cold Spring Harbor Symposia on Quantitative Biology 59 11-17
132. Sherr CD and Roberts JM (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Genes and Development 9 1149-1163
133. Smith ML and Fornace AJ (1995) Genomic instability and the role of p53 mutations in cancer cells. Current Opinion in Oncology 7 69-75
134. Smith ML, Chen IT, Zhan Q, O'Connor PM and Fornace Jr AJ (1995) Involvement of the p53 tumor suppressor in repair of u.v. type damage. Oncogene 10 1053-1059
135. Srivastava S, Zou Z, Pirollo K, Blattner W and Chang EH (1990) Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348 747- 749
136. Stark GR (1993) Regulation and mechanisms of mammalian gene amplification. Advances in Cancer Research 61 87-113
137. Stewart N, Hicks GG, Paraskevas F and Mowat M (1995) Evidence for a second cell cycle block at G2/M by p53. Oncogene 10 109-115
138. Symonds H, Krall, L, Remington L et al (1994) p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78 703-711
139. Tlsty TD, Briot A, Gualberto A et al (1995) Genomic instability and cancer. Mutation Research 337 1-7
140. Tsukada T, Tomooka Y, Takai S et al (1993) Enhanced proliferative potential in culture of cells from p53-deficient mice. Oncogene 8 3313-3322
141. Waga S, Hannon GJ, Beach D and Stillman B (1994) The p21CIP1/WAF1 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369 574-578
142. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A and Schmidt EV (1994) Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369 669-671
143. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR and Harris CC (1994) Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity and association with transcription factor ERCC3. Proceedings of the National Academy of Sciences of the USA 91 2230-2234
144. Wang XW, Yeh H, Schaeffer L et al (1995) p53 modulation of TFIIH-associated nucleotide excision repair activity. Nature Genetics 10 188-195
145. Weinberg RA (1991) Tumor suppressor genes. Science 254 1138
146. Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81 323-330
147. White AE, Livanos EM and Tlsty TD (1994) Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes and Development 8 666-677
148. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D (1993a) p21CIP1/WAF1 is a universal inhibitor of cyclin kinases. Nature 366 701-704
149. Xiong Y, Zhang H and Beach D (1993b) Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes and Development 7 1572-1583
150. Yahanda A, Bruner J, Donehower LA and Morrison RS (1995) Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas. Molecular and Cellular Biology 15 4249-4259
151. Yin Y, Tainsky MA, Bischoff FZ, Strong LC and Wahl GM (1992) Wild type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70 937-948
152. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A and Oren M (1991) Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352 345-347
153. Zhou P, Jiang W, Weghorst CM and Weinstein IB (1996) Overexpression of cyclin D1 enhances gene amplification. Cancer Research 56 36-39.